TickerFacts.

Belite Bio, Inc (BLTE): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$37.06M
Year ended 2025-12-31
2021-12-31: -$7.55M2022-12-31: -$11.85M2023-12-31: -$29.90M2024-12-31: -$29.35M2025-12-31: -$37.06M-$37.06M
2021-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$37.06Mn/m2026-03-31, From 2025-01-01
2024-12-31-$29.35Mn/m2026-03-31, From 2024-01-01
2023-12-31-$29.90Mn/m2026-03-31, From 2023-01-01
2022-12-31-$11.85Mn/m2025-03-17, From 2022-01-01
2021-12-31-$7.55Mn/a2024-03-12, From 2021-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Belite Bio, Inc (BLTE)2025-12-31-$37.06Mn/m
Spyre Therapeutics, Inc. (SYRE)2024-12-31-$157.41Mn/m
Maravai Lifesciences Holdings, Inc. (MRVI)2025-12-31-$70.72Mn/m
NewAmsterdam Pharma Co N.V. (NAMS)2025-12-31-$148.03Mn/m
MannKind Corp (MNKD)2025-12-31$13.69M-58.3%
Cryoport, Inc. (CYRX)2025-12-31-$25.02Mn/m
Kiniksa Pharmaceuticals International, plc (KNSA)2025-12-31$136.42M+436.8%
Disc Medicine, Inc. (IRON)2025-12-31-$181.33Mn/m
Ocular Therapeutix, Inc (OCUL)2025-12-31-$216.89Mn/m

Compare BLTE, SYRE, MRVI, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗